Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-03
2005-05-03
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S394000
Reexamination Certificate
active
06887878
ABSTRACT:
A compound having the following formula I:where R1is an alkyl group or an alkenyl group, X representsR2is selected from the group consisting of a halogen (o, m, p) group such as F, Cl, Br or I, —NH2, —NO2and a hydrogen group, R3is a hydrogen group or OH. The compound has pharmacologically α2-adrenergic/5-HT2Aantagonist activity, 5-HT re-uptake activity, and anti-oxidant activity. The compound is produced by preparing 4-epoxy isoeugenol, mixing piperazine dissolved in methanol with the 4-epoxy isoeugenol to reflux at 100° C. for approximately 2 to approximately 6 hours, removing the methanol, passing the mixture through a silica gel column chromatography after the removing step, eluting the passed mixture with n-hexane and ethyl acetate, drying the eluted mixture, and crystallizing the dried mixture with methanol.
REFERENCES:
patent: 966493 (1964-08-01), None
Gupta et al. Arzneim.-Forsch./Drug Res. 28(1), p. 241-246 (1978).*
Dunn et al., Bibliographic record of “The reductions in sweetened milk intake induced byinterleukin-1 and endotoxin are not prevented by chronic antidepressant treatment,” http://www.hint.org.tw/cgi-bin/ovidweb/ovidweb.cgi., 2001.
Girard et al., “A New Synthetic Flavonoid Protects Endothelium Derived Relaxing Factor-induced Relaxation in Rabbit Arteries in Vitro: Evidence for Superoxide Scavenging,” Biochemical Pharmacology, vol. 49, No. 10, pp. 1553-1539, 1995.
Altavilla et al., “The Lazaroid, U-74389G, inhibits inducible nitric oxide synthase activity, reverses vascular failure and protects against endotoxin shock,”European Journal of Pharmacology, vol. 369, pp. 49-55, 1999.
Aubriot et al., “New Series of Aryloxpropanolamines with Both Human β3-Adrenoceptor Agonistic Activity and Free Radical Scavenging Properties ,” Bioorganic&Medical Chemistry Letters, vol. 12, pp. 209-212, 2002.
Cohen et al., “Evidence that Blood Pressure Reduction by Serotonin Antagonists is Related to Alpha Receptor Blockade in Spontaneously Hypertensive Rats,” Hypertension vol. 5, No. 5, pp. 676-681, Sep.-Oct., 1983.
Correa et al., “Central α1-Adrenoceptors Mediate the Pressor Response to Intracerebroventricular Injection of Noradrenaline in Unanesthetized Rats,” Neuropharmacology vol. 34, No. 7, pp. 793-798, 1995.
Curro et al., “Interaction Between Alpha Adrenergic and Serotonergic Activation of Canine Saphenous Veins,” The Journal of Pharmacology and Experimental Therapeutics vol. 207, pp. 936-949, 1978.
Diaz-Cabiale et al., “Galanin/alpha2-receptor interactions in central cardiovascular control,” Neuropharmacology vol. 39, pp. 1377-1385, 2000.
Dobrucki et al., “Central Hypotensive Action of Clonidine Requires Nitric Oxide,” Circulation, vol. 104, pp. 1884-1886, Oct. 16, 2001.
Duan et al., “Enhancement of Clonidine-Induced Analgesia by Lesions Induced with Spinal and Intracerbroventricular Administration of 5, 7-Dihydroxytryptamine,” Neuropharmacology vol. 26, No. 4, pp. 323-329, 1987.
Duka et al., “Role of the Postsynaptic α2-adrenergic receptor subtypes in catecholamine-induced vasoconstriction,” General Pharmacology vol. 34, pp. 101-106, 2000.
Elenkov et al., “Modulation of lipopolysaccharide-induced tumor necrosis factor-αproduction by selective α-and β-adrenergic drugs in mice,” Journal of Neuroimmunology vol. 61, pp. 123-131, 1995.
Fujimoto et al., “Denopamine as an α1H-adrenoceptor antagonist in isolated blood vessels,” European Journal of Pharmacology vol. 280, pp. 143-147, 1995.
Glaser et al., Bibliographic record of “Stress depresses interferon production by leukocytes concomitant with a decrease in natural killer cell activity, ”http://www.int/org.tw/cgi-bin/ovidweb/ovidweb/cgi.
Hasko et al., “Differential effect of selective block of α2-adrenoreceptors on plasma levels of tumour necrosis factor-α, interleukin-6 and corticosterone induced by bacterial lipopolysaccharide in mice,” Journal of Endocrinology vol. 144, pp. 457-462, 1995.
Hasko et al., “Differential effect of selective block of α2-adrenoreceptors on plasma levels of tumour necrosis factor-α, interleukin-6 and corticosterone induced by bacterial lipopolysaccharide in mice,” Journal of Endocrinology vol. 144, pp. 457-462, 1995.
Hatanaka et al., “Biochemical Profile of YM992, a Novel Selective Serotonin Reuptake Inhibitor with 5-HT2AReceptor Antagonistic Activity,” Neuropharmacology vol. 35, No. 11, pp. 1621-1626, 1996.
Helmeste et al., “Inhibitation of Platelet Serotonin Uptake by Cytochrome P450 Inhibitors Miconazole and Econazole,” Life Sciences vol. 62, No. 24, pp. 2203-2208, 1998.
Hirata et al., “Effects of endothelin receptor antagonists on endothelin-1 and inducible nitric oxide synthase genes in a rat endotoxic model,” Clinical Science, pp. 332-335, 2002.
Huang et al., “Inhibitory effect of DCDC on lipopolysaccharide-induced nitric oxide synthesis in RAW 264.7 cells,” Life Sciences vol. 68, pp. 2435-2447, 2001.
Huang et al., “Ferulidiol : A Vasodilatory and Antioxidant Adrenoceptor and Calcium Entry Blocker, with Ancillary β2-Agonist Activity,” Drug Development Research 47:77-89 (1999).
Huang et al., “A New Aspect of View in Synthesizing New Type β-adrenoceptor Blockers with Ancillary Antioxidant Activities,” Bioorganic & Medicinal Chemistry vol. 9, pp. 1739-1746, 2001.
Ko et al., “β-Blocker Therapy and Symptoms of Depression, Fatigue, and Sexual Dysfunction,” JAMA vol. 288, No. 3, pp. 351-357, Jul. 17, 2002.
Koyama, “Participation of central α-receptors on hemodynamic response to E. Coil endotoxin,” American Journal Physiology vol. 247, pp. R655-R662, 1984.
Krege et al., “Affinity of trazodone for human penileα1--and α2-adrenoceptors,” BJU International vol. 85, pp. 959-961, 2000.
Kubo et al., “Cardiovascular effects in rats of alpha1and alpha2adrenergic agen injected into the nucleus tractus solitarii,” Naunyun-Schmiedeberg's Archives of Pharmacology vol. 335, pp. 274-277, 1987.
Lin et al., “Systemic Administration of Lipopolysaccharide Induces Release of Nitric Oxide and Glutamate and c-fos Expression in the Nucleus Tractus Solitarii of Rats,” Hypertension 33:1218-1224, 1999.
Llado et al., “The α2-adrenoceptor antagonist idazoxan is an agonist at 5-HT1Aautoreceptors modulating serotonin synthesis in the rat brainin vivo”, Neuroscience Letters vol. 218, pp. 111-114, 1996.
Loegering et al., “The Antioxidant, U74389, Ameliorates the Depression of Vascular Reactivity Caused by Lipopolysaccharide”, Life Sciences, vol. 57, No. 20, pp. 321-326, 1995.
Maitra et al., “Alterations in Tissue Glucose Uptake During the Hyperglycemic and Hypoglycemic Phases of Sepsis”, Hock vol. 13, No. 5, pp. 379-385, 2000.
Molina-Holgado et al., “Endotoxin Administration Induced Differential Neurochemical Activation of the Rat Brain Stem Nuclei,” Brain Research Bulletin, vol. 40, No. 3, pp. 151-156, 1996.
Murphy et al., “Characterization of Alpha-2 Adrenergic Receptors in the OK Cell, an Opossum Kidney Cell Line,” The Journal of Pharmacology and Experimental Therapeutics vol. 244, No. 2, pp. 571-578, 1987.
Nickola et al., “Antidepressant Drug-Induced Alterations in Neuron-Localized Tumor Necrosis Factor-αmRNA and α2-Adrenergic Receptor Sensitivity,” The Journal of Pharmacology and Experimental Therapeutics vol. 297, No. 2, pp. 680-687, 2001.
Owens et al., “Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites,” The Journal of Pharmacology and Experimental Therapeutics vol. 283, No. 3, pp. 1305-1322, 1997.
Pitzalis et al., “Depression but not anxiety influence
Bushnell , Esq. Robert E.
Ing-Jun Chen
Raymond Richard L.
Syn-Rech Chem & Phan Co., Ltd
LandOfFree
KMST isoeugenol derivatives and pharmaceutical activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with KMST isoeugenol derivatives and pharmaceutical activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and KMST isoeugenol derivatives and pharmaceutical activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3421942